Connect Biopharma Holdings Limited Ordinary Shares
CNTBStock
$2.33+67.02%52W
Market Cap$153.00M
P/E—
Div yield—
Beta-0.24
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-4.47%
Price vs S&P 500 (4W)14.72%
VGM Score26.51
Market Capitalization$153.00M
Earnings Surprise History
Q1 26-0.34est. -1.54
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.27
4.23
4.23
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTBConnect Biopharma Holdings Limited Ordinary Shares | F | F | C | $2.33 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Connect Biopharma is a clinical-stage biopharmaceutical company developing next-generation immune modulators to treat autoimmune diseases and inflammatory conditions. The company leverages expertise in T cell modulation to build a pipeline of small molecule and antibody candidates targeting key inflammation pathways. Its lead programs include CBP-201, CBP-307, and CBP-174.